Boltz raises $110M Series A for AI biomolecular design, already working with 6 top pharma cos

GabriCorso · x · 2026-11-19

Boltz, an AI-powered biomolecular design company, has raised a $110M Series A led by Bessemer Venture Partners. Molecular token usage by its users has grown 50-fold since June, and it counts partnerships with 6 of the world's 20 largest pharma companies. Founder Gabri Corso and team aim to bring AI-driven biomolecular design to every scientist.

Original post →

More from Venture

Venture channel →